7/9/2014 | PP | NanoViricides settles $5 million placement of convertible debentures
|
6/25/2014 | PP | NanoViricides amends terms of warrants sold in private placements
|
1/21/2014 | PP | NanoViricides arranges $20 million registered direct offering of units
|
9/12/2013 | PP | NanoViricides seals $10.33 million registered direct offering of units
|
9/10/2013 | PP | NanoViricides plans $9.9 million registered direct offering of units
|
2/1/2013 | PP | NanoViricides arranges $6 million placement of convertible debentures
|
12/28/2012 | PP | NanoViricides plans $2.5 million registered direct sale of preferreds
|
12/3/2012 | CVPF | NanoViricides lifts shelf for stock, debt, preferreds to $57.5 million
|
10/26/2012 | CVPF | NanoViricides registers $40 million shelf for debt, preferreds
|
6/28/2012 | PP | NanoViricides negotiates $5 million public offering of 10% preferreds
|
11/1/2011 | PP | NanoViricides negotiates $5 million public offering of 10% preferreds
|
7/27/2011 | PP | NanoViricides wraps $2.5 million of $15 million preferreds offering
|
4/20/2011 | PP | NanoViricides seals another $5 million of $7.5 million preferreds sale
|
4/19/2011 | PP | NanoViricides reports $2.5 million registered offering of preferreds
|
12/22/2010 | PP | NanoViricides wraps $5 million private placement of 10% preferreds
|
9/21/2010 | PP | NanoViricides plans $5 million follow-on offering of 10% preferreds
|
5/12/2010 | PP | Market Commentary: Chesapeake eyes another $600 million; Sequenom plans issue; Mesoblast gets acquisition funding
|
5/12/2010 | PP | New Issue: NanoViricides prices $5 million 10% convertible preferred shares
|
3/4/2010 | CVHY | NanoViricides files $40 million shelf for debt, preferreds and stock
|
10/6/2009 | PP | New Issue: NanoViricides details $5.1 million private placements of common stock
|
10/5/2009 | PP | NanoViricides takes in $4.3 million through common stock placement
|
7/10/2009 | PP | New Issue: NanoViricides consummates $1.05 million private placement of shares
|
8/29/2008 | PP | New Issue: NanoViricides seals $3.29 million private placement of shares
|
10/18/2007 | PP | New Issue: NanoViricides wraps $1.75 million sale of shares, warrants
|
8/29/2006 | BT | NanoViricides: Three bird flu and influenza drugs now in pipeline
|
8/10/2006 | BT | NanoViricides scheduled to begin preclinical testing of rabies drug
|
4/19/2006 | BT | NanoViricides retires 833,600 shares of unauthorized stock, cancels 700,000 options
|
3/20/2006 | BT | NanoViricides to file IND after positive results in FluCide-1 studies
|
2/27/2006 | BT | NanoViricides learns the early study results for anti-flu drug FluCide-I
|
12/5/2005 | BT | NanoViricides' base polymer found safe in animals, study says
|
12/1/2005 | BT | Market Commentary: Rigel Pharma tromped; Oxigene, Biopure launch follow-on deals; Lexicon, LabCorp, Quigley higher
|
11/16/2005 | BT | Market Commentary: Gilead gains on Roche settlement; AtheroGenics sinks; Amylin rises
|
11/7/2005 | BT | NanoViricides' anti-viral drug FluCide-I safe for animals, study shows
|
10/31/2005 | BT | NanoViricides begins preclinical studies for flu drug FluCide-I
|
10/12/2005 | BT | Market Commentary: Vical falls 20% on PIPEs deal; Threshold, Dynavax off on stock sales; Pharma Product higher
|
10/10/2005 | BT | Market Commentary: Holiday makes for thin market; Gilead, niche flu drug names go higher; Human Genome lower yet
|
10/7/2005 | BT | Market Commentary: CoTherix off on follow-on deal; Human Genome slide unabated; Cytogen higher; flu names soar
|
7/13/2005 | BT | Market Commentary: Genentech floats $2 billion in bonds; Advanced Medical Optics convert dished up; Mylan talk out
|
7/13/2005 | BTPP | NanoViricides prices convertible debenture offering
|